Accordingly, also studies in patients with relapsed CLL following SCT support that ibrutinib augments the GvH versus-leukemia (GVL) benefit likely through ITK inhibition [215]. The gene discussed is ITK; the disease is B-cell chronic lymphocytic leukemia.